drugset
drugset / Trial / NCT07387081

Phase II Study of LM-24C5

NCT07387081 ↗

Phase 2 Recruiting 130 enrolled LaNova Medicines Limited
Non-randomizedSequentialOpen-labelTreatment

Summary

This study is to evaluate the efficacy and safety of the LM-24C5 in combination with other therapies in subjects with CEACAM5-positive advanced solid tumor

Timeline

Start
2025-12-15
Primary completion
2028-05-21
Completion
2028-10-25

Drugs

EvaluationDrugModalityDoseRoute
Subject LM-24C5 Unknown — Intravenous
Background Bevacizumab Monoclonal antibody — Intravenous
Background Docetaxel Small molecule — Intravenous
Background Penpulimab Monoclonal antibody — Intravenous
Background Tipiracil Small molecule — Oral
Background Trifluridine Small molecule — Oral

Indications

No indication recorded.